Keros Therapeutics Management
Management criteria checks 2/4
Keros Therapeutics' CEO is Jas Seehra, appointed in Dec 2015, has a tenure of 8.5 years. total yearly compensation is $8.93M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 0.7% of the company’s shares, worth $11.52M. The average tenure of the management team and the board of directors is 3.6 years and 4.3 years respectively.
Key information
Jas Seehra
Chief executive officer
US$8.9m
Total compensation
| CEO salary percentage | 7.3% |
| CEO tenure | 8.5yrs |
| CEO ownership | 0.7% |
| Management average tenure | 3.6yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers
Jun 10Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?
Apr 23
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Sep 24We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth
Jun 10Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Dec 25Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Sep 08Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07
Aug 04Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Apr 29We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Jan 24Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Oct 10We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
May 05Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?
Mar 13We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate
Jan 19Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?
Nov 27Keros Therapeutics prices equity offering at $50
Nov 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$160m |
| Dec 31 2023 | US$9m | US$649k | -US$153m |
| Sep 30 2023 | n/a | n/a | -US$142m |
| Jun 30 2023 | n/a | n/a | -US$127m |
| Mar 31 2023 | n/a | n/a | -US$116m |
| Dec 31 2022 | US$6m | US$611k | -US$105m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | n/a | n/a | -US$79m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$7m | US$557k | -US$59m |
| Sep 30 2021 | n/a | n/a | -US$61m |
| Jun 30 2021 | n/a | n/a | -US$53m |
| Mar 31 2021 | n/a | n/a | -US$49m |
| Dec 31 2020 | US$10m | US$521k | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$39m |
| Jun 30 2020 | n/a | n/a | -US$31m |
| Mar 31 2020 | n/a | n/a | -US$23m |
| Dec 31 2019 | US$695k | US$485k | -US$14m |
Compensation vs Market: Jas's total compensation ($USD8.93M) is above average for companies of similar size in the US market ($USD5.68M).
Compensation vs Earnings: Jas's compensation has increased whilst the company is unprofitable.
CEO
Jas Seehra (68 yo)
8.5yrs
Tenure
US$8,932,076
Compensation
Dr. Jasbir S. Seehra, also known as Jas, Ph D., has been Chief Executive Officer and Director at Keros Therapeutics Inc., since December 2015 and serves as its President since December 2015. Dr. Seehra had...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.5yrs | US$8.93m | 0.70% $ 11.5m | |
| Chief Financial Officer | 4.3yrs | US$2.20m | 0% $ 0 | |
| Chief Operating Officer | 2.3yrs | US$4.69m | 0% $ 0 | |
| Senior VP | 4.2yrs | no data | no data | |
| Senior Vice President of Human Resources | 3yrs | no data | no data | |
| Senior Vice President of Program & Portfolio Management | 1.2yrs | no data | no data |
3.6yrs
Average Tenure
54yo
Average Age
Experienced Management: KROS's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.5yrs | US$8.93m | 0.70% $ 11.5m | |
| Independent Chairman | 4.3yrs | US$409.37k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$385.86k | 0% $ 0 | |
| Director | no data | no data | 0.00055% $ 9.0k | |
| Independent Director | 8.2yrs | US$388.48k | 0.0033% $ 54.2k | |
| Independent Director | 3.5yrs | US$396.98k | 0.12% $ 2.0m | |
| Independent Director | 8.2yrs | US$390.56k | 0% $ 0 | |
| Independent Director | 1.1yrs | US$1.02m | 0.046% $ 759.2k | |
| Independent Director | 4.3yrs | US$388.48k | 0.097% $ 1.6m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.3yrs
Average Tenure
61yo
Average Age
Experienced Board: KROS's board of directors are considered experienced (4.3 years average tenure).